What You Should Know
- St. Louis-based Aurenar has closed an oversubscribed $5.7M seed financing co-led by the Go Red for Women Venture Fund™ (part of American Heart Association Ventures™) and Solas BioVentures, with participation from BJC Health and Kaleida Capital.
- Funds the clinical advancement of V-Link™, a non-invasive, single-use transauricular vagus nerve stimulation (taVNS) platform engineered to curtail life-threatening inflammatory responses in ICU patients.
- WashU clinical trials demonstrated that taVNS reduced moderate-to-severe vasospasm by >40%, lowered pro-inflammatory cytokines, improved functional recovery, and drove a 20% reduction in 30-day modifiable hospitalization costs.
- Features a simple, wireless ear-clip design that allows neuro-ICU physicians and nursing staff to initiate targeted bioelectric therapy without complex surgical implantation or specialized training.
- Proceeds directly fund final device engineering, verification and validation (V&V) testing, and upcoming FDA pivotal trial regulatory submissions.
Transauricular Vagus Nerve Stimulation & Bioelectric Anti-Inflammation
Aurenar’s V-Link platform bridges non-invasive neuro-technology with neurocritical care workflows:
- Transauricular Vagus Nerve Stimulation (taVNS): Delivers precise electrical stimulation to the auricular branch of the vagus nerve via the outer ear, activating the body’s endogenous cholinergic anti-inflammatory pathway without surgical implantation.
- Cytokine Suppression & Vasospasm Control: Suppresses key pro-inflammatory cytokines (TNF-α, IL-6) in blood plasma and cerebrospinal fluid (CSF), mitigating radiographic cerebral vasospasm by >40%.
- Single-Use Wireless ICU Form Factor: Engineered as a single-use, wireless ear-worn patch that integrates seamlessly into ICU nursing workflows without requiring specialized surgical support.
- Empirical Validation (WashU Medicine): Spun out of Washington University in St. Louis research led by Dr. Eric Leuthardt and Dr. Anna Huguenard, clinical trial data proved higher rates of favorable functional recovery and a 20% drop in 30-day modifiable care costs.
“In the intensive care unit, it’s not just the diagnosis that brings you in, it’s all of the things that happen afterwards that define a patient’s outcome,” stated Dr. Eric Leuthardt, Founder and CEO of Aurenar. “With the support of our investor group, every dollar of this round is committed to milestones that help us improve outcomes for patients in the most critical moments of their care.”
As Aurenar initiates V&V testing and prepares its FDA pivotal trials, it provides a compelling operational model for how bioelectric therapeutics will redefine critical care medicine.
